Skip to main content
Aptamer Sciences Inc logo

Aptamer Sciences Inc — Investor Relations & Filings

Ticker · 291650 ISIN · KR7291650000 KO Manufacturing
Open in API
Filings indexed 230 across all filing types
Latest filing 2022-01-27 Director's Dealing
Country KR South Korea
Listing KO 291650

About Aptamer Sciences Inc

https://aptsci.com/en/

Aptamer Sciences Inc. is a clinical-stage biopharmaceutical company specializing in aptamer technology. The company has established a proprietary, integrated platform for the discovery and development of aptamer-based therapeutics and diagnostics. Its primary focus is on oncology, utilizing its Aptamer-Drug Conjugate (ApDC™) platform to create targeted cancer treatments. The lead candidate, AST-201, is an ApDC targeting the GPC3 protein, which is highly expressed in solid tumors such as liver cancer. The company is advancing AST-201 through clinical trials to evaluate its safety and efficacy. The development pipeline also includes other innovative platforms like Aptamer Radioligand Conjugates (ApRC) and Aptamer Immune Stimulator Conjugates (ApIS), aimed at addressing unmet medical needs in hemato-oncology and other areas. Aptamer Sciences leverages its technology to develop novel therapies with the potential for high specificity and efficacy.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership changes of a specific executive (Kim Ki-seok) of Aptamer Sciences. This type of filing is a standard regulatory requirement for insider trading/shareholding disclosures, which corresponds to the 'Director's Dealing' category.
2022-01-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service and Korea Exchange. This type of filing is a standard regulatory requirement for insiders (directors/executives) to disclose changes in their shareholdings, which corresponds to the 'Director's Dealing' category.
2021-12-31 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a formal notice regarding the closure of the shareholder register (주주명부폐쇄) to determine shareholders eligible to vote at the upcoming Annual General Meeting (제11기 정기주주총회). This is a standard regulatory announcement regarding corporate governance and shareholder rights, which does not fit into specific categories like financial reports or dividend announcements. Therefore, it is classified as a general regulatory filing.
2021-12-14 Korean
기타경영사항(특허권취득)(자율공시)(비소세포성 폐암 진단용 단백질 바이오마커 패널 및 이를 이용한 비소세포성 폐암 진단 방법)
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure from Aptamer Sciences regarding the acquisition of a patent for a lung cancer diagnostic method. It is filed as a 'voluntary disclosure' (자율공시) under the category of 'Other Management Matters' (기타 경영사항). Since it does not fit into specific categories like financial reports, board changes, or dividends, and is a standard regulatory announcement of a corporate event, it falls under the 'Regulatory Filings' (RNS) category.
2021-11-26 Korean
분기보고서 (2021.09)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Aptamer Sciences' covering the period from 2021.01.01 to 2021.09.30. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-15 Korean
본점소재지변경
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement regarding a change in the company's headquarters location (본점소재지변경). It does not fit into specific categories like financial reports, dividends, or director dealings. As it is a standard regulatory disclosure filed with the exchange (KRX) that does not fall into the other specialized categories, it is classified as a general regulatory filing.
2021-08-18 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.